Tesamorelin is a growth peptides research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
Tesamorelin is a synthetic analogue of human GHRH consisting of the full 44-amino acid native GHRH sequence conjugated at the N-terminus to trans-3-hexenoic acid. This modification protects the peptide from DPP-IV cleavage at the His²-Ala³ bond — the primary degradation site of native GHRH — while preserving full GHRHR agonist activity. Tesamorelin represents the longest GHRH sequence used as a therapeutic and research compound, contrasting with shorter analogues (sermorelin at 29 AA, CJC-1295 Without DAC at 29 AA with modifications). Its regulatory approval for HIV-associated lipodystrophy-related visceral fat accumulation in 2010 provides an unusually complete translational pharmacology dataset for a research peptide.
The primary mechanistic research interest in tesamorelin is the characterisation of sustained, physiologically patterned GH secretion and its metabolic consequences. Unlike CJC-1295 With DAC — which produces sustained supraphysiological GH elevation via albumin binding — tesamorelin's trans-3-hexenoic acid modification provides moderate DPP-IV protection without albumin binding, resulting in an intermediate pharmacokinetic profile. Clinical studies document significant reductions in visceral adipose tissue (VAT) measured by CT imaging after 26 weeks of administration, with preserved insulin sensitivity compared to exogenous GH. This metabolic selectivity is a central focus of tesamorelin's research profile.
PeptidesFromChina.co supplies tesamorelin as lyophilized powder at ≥98% purity, verified by HPLC and confirmed by mass spectrometry. Certificates of Analysis available per batch. Wholesale quantities on request. This compound is for laboratory research use only.
| Chemical Class | N-terminally Modified GHRH(1-44) Analogue |
|---|---|
| Modification | Trans-3-hexenoic acid conjugated at N-terminus |
| CAS Number | 218949-48-9 |
| Molecular Weight | 5135.9 Da |
| Sequence Length | 44 amino acids (full-length GHRH sequence) |
| Receptor Target | GHRHR (Growth Hormone-Releasing Hormone Receptor) |
| Synonyms | TH9507 |
| Half-life (research) | ~26–30 min (clinical plasma PK) |
| Storage | -20°C lyophilized; 4°C reconstituted (up to 14 days) |
| Molecular Formula | N/A — 44-aa GHRH analogue; see COA |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| Tesamorelin | 2 mg | 10 vials | ≥98% | In Stock | $61.00 |
| Tesamorelin | 5 mg | 10 vials | ≥98% | In Stock | $125.00 |
| Tesamorelin | 10 mg | 10 vials | ≥98% | In Stock | $183.00 |
| Tesamorelin | 20 mg | 10 vials | ≥98% | In Stock | $325.00 |
Testing method: HPLC / LC-MS (["HPLC","LC-MS","Water Content","Assay"]). Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis: Simple COA. Documentation is available for every batch sold.
The largest body of clinical evidence for tesamorelin addresses HIV-associated lipodystrophy — a metabolic complication of antiretroviral therapy characterised by central visceral fat accumulation with peripheral lipoatrophy. The LIPO-010 and companion phase III trials documented significant reductions in CT-measured visceral adipose tissue (approximately 15–17% over 26 weeks versus placebo) without the hyperglycaemia or IGF-1 overshoot seen with exogenous GH. Preclinical HAART-treated rodent models with lipodystrophy phenotypes use tesamorelin as the positive control in metabolic reversal studies. The selective visceral fat effect is attributed to restoration of physiological GH pulsatility rather than pharmacological GH excess.
Tesamorelin's 44-amino acid sequence activates GHRHR with high potency and produces a GH pulse with amplitude and kinetics studied using frequent blood sampling protocols (every 10–20 min). Compared to sermorelin and CJC-1295 Without DAC in comparative pituitary cell and in vivo studies, tesamorelin produces equivalent receptor activation per mole but with moderately extended stability. The compound is used in somatopause research — the age-related decline in GH pulse frequency and amplitude — where restoration of pulsatile GH via GHRHR stimulation is compared with exogenous GH administration for downstream metabolic and body composition endpoints.
An exploratory strand of tesamorelin research addresses its CNS effects, motivated by GH and IGF-1 receptors' widespread expression in the brain and the established role of the GH axis in neuronal metabolism. A randomised trial in older adults (TRIUMPHANT-AD) investigated tesamorelin's effects on cognitive measures and MRI-measured brain structure, noting the relationship between GH axis activity, hippocampal volume, and executive function. Preclinical rat models of age-associated cognitive decline use tesamorelin to characterise GH-dependent neuroplasticity endpoints (BDNF expression, synaptic density) — areas that overlap with the research on GH secretagogues in neurodegeneration.
GH deficiency and reduced GH pulsatility are associated with hepatic steatosis. Tesamorelin has been investigated in NAFLD in the context of HIV-associated metabolic disease, with MRI-spectroscopy-measured hepatic fat fraction as the primary endpoint. The proposed mechanism involves GH-stimulated lipolysis in visceral adipose tissue reducing ectopic lipid deposition in the liver, compounded by direct GH receptor-mediated effects on hepatic lipid metabolism. This area connects with the broader research interest in GHRH analogues as metabolic tools in fatty liver models.
Both are GHRH receptor agonists with extended half-life relative to sermorelin, but via different mechanisms. CJC-1295 With DAC binds albumin via the DAC modification, extending half-life to ~6–8 days and producing persistent, supraphysiological GH elevation. Tesamorelin uses a trans-3-hexenoic acid N-terminal modification that confers DPP-IV resistance without albumin binding, producing a moderate half-life (~26–30 min) and pulsatile GH release. Tesamorelin's pulsatile profile is associated with better insulin sensitivity and more physiological IGF-1 response in clinical studies, distinguishing it metabolically from the sustained GH elevation profile of CJC-1295 With DAC.
Yes. The trans-3-hexenoic acid–peptide conjugate is stable under standard lyophilized peptide storage conditions (−20°C, dry, dark). The hexenoic acid modification is an amide bond at the N-terminus, which is not uniquely susceptible to hydrolysis under storage conditions. Reconstituted solutions should be used within 14 days when stored at 4°C. Avoid alkaline pH (above 8.0) in reconstitution buffers, as this can increase hydrolysis rates of all peptide bonds.
While tesamorelin's clinical approval is in the HIV-lipodystrophy indication, its mechanism — restoration of physiological GH pulsatility via GHRHR stimulation — is relevant to any research context involving somatopause, metabolic GH deficiency, or visceral adiposity. The extensive Phase II/III clinical dataset provides pharmacodynamic benchmarks (GH pulse AUC, IGF-1 response, VAT reduction kinetics) that researchers can use to calibrate preclinical model protocols and translate animal study findings.
Tesamorelin is available through PeptidesFromChina.co in wholesale quantities with tiered pricing. Standard vial sizes and bulk pricing are provided upon request following account verification. Contact us via the Request page.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.